Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
June 11, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
May 25, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces an Additional Nature Publication for AUTO1

LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
May 21, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021

Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...
May 12, 2021 10:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress

AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 ...
May 06, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress

LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 26, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call on May 6

LONDON, April 26, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 20, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 19, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman

LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 01, 2021 16:01 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Investor Conferences Through April

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right